Amundi’s Prothena Corp PRTA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-2,014
Closed -$22.8K 2057
2025
Q1
$22.8K Buy
2,014
+60
+3% +$848 ﹤0.01% 1853
2024
Q4
$27.7K Sell
1,954
-11,732
-86% -$185K ﹤0.01% 1873
2024
Q3
$228K Sell
13,686
-2,213
-14% -$47.6K ﹤0.01% 1627
2024
Q2
$319K Buy
+15,899
New +$344K ﹤0.01% 1456
2024
Q1
Sell
-166,631
Closed -$6.6M 2063
2023
Q4
$6.6M Sell
166,631
-9,941
-6% -$383K ﹤0.01% 937
2023
Q3
$7.78M Buy
176,572
+67,721
+62% +$4.02M ﹤0.01% 888
2023
Q2
$7.48M Buy
108,851
+106,070
+3,814% +$6.84M ﹤0.01% 911
2023
Q1
$134K Hold
2,781
﹤0.01% 1675
2022
Q4
$156K Sell
2,781
-250
-8% -$14.6K ﹤0.01% 1546
2022
Q3
$176K Buy
+3,031
New +$95.8K ﹤0.01% 1472

Other funds holding PRTA

Amundi's PRTA Position: Q2 2025 in Review

Amundi sold out of Prothena Corp (PRTA) in Q2 2025, closing a stake of 2,014 shares — an estimated $22.8K sold.

Amundi first reported a position in PRTA in Q3 2022 and held it in 10 quarters. The position peaked at $7.78M in Q3 2023. 188 funds tracked by Wall St. Rank hold PRTA as of Q2 2025.

  • Amundi reported no remaining Prothena Corp position as of Q2 2025 after selling out during the quarter.
  • Amundi sold 2,014 Prothena Corp shares in Q2 2025, an estimated $22.8K.
  • Amundi first reported a position in Prothena Corp in Q3 2022 and held it in 10 quarters.
  • Amundi's Prothena Corp position peaked at $7.78M in Q3 2023.
  • 188 funds tracked by Wall St. Rank held Prothena Corp as of Q2 2025.

Based on Amundi's 13F filing for Q2 2025, filed 13 Aug 2025.